# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
GMP grade plasmid DNA to serve as a direct therapeutic targeting various indicationsCharles River Laboratories International, I...
Argus Research analyst David Toung maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $200 to $290.
Next-generation AAV gene therapy to target debilitating pain disorders Charles River Laboratories International, Inc. (NYSE:CR...
Wheeler Bio, Inc., an agile contract development and manufacturing organization (CDMO), announced today a new strategic agreeme...
Charles River Laboratories International, Inc. (NYSE:CRL) today announced a strategic agreement with Wheeler Bio, Inc., an ant...